SAPHNELO™ is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. It is a fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, blocking the activity of type I IFNs.
SAPHNELO™ is not indicated for severe active lupus nephritis or severe active CNS lupus.
